These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 23047532

  • 1. Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience.
    Cardiel MH, Pons-Estel BA, Sacnun MP, Wojdyla D, Saurit V, Marcos JC, Pinto MR, Cordeiro de Azevedo AB, da Silveira IG, Radominski SC, Ximenes AC, Massardo L, Ballesteros F, Rojas-Villarraga A, Oñate RV, Hernandez MP, Esquivel-Valerio JA, García-De La Torre I, Khoury VJ, Millán A, Soriano ER, GLADAR.
    J Clin Rheumatol; 2012 Oct; 18(7):327-35. PubMed ID: 23047532
    [Abstract] [Full Text] [Related]

  • 2. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T, Pincus T.
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [Abstract] [Full Text] [Related]

  • 3. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
    Nikolaisen C, Kvien TK, Mikkelsen K, Kaufmann C, Rødevand E, Nossent JC.
    Scand J Rheumatol; 2009 Dec; 38(4):240-5. PubMed ID: 19229766
    [Abstract] [Full Text] [Related]

  • 4. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
    Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, Paulus HE, Xia HA, Leff JA, RADIUS Investigators.
    Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
    [Abstract] [Full Text] [Related]

  • 5. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 6. [Descriptive study of the use of DMARD in patients with rheumatoid arthritis or persistent arthritis who start drug treatment in Spain (FIRST)].
    Blanco FJ, Ballina J, Carbonell J, Martín-Mola E, Tornero J, Ramírez E, Galván J.
    Reumatol Clin; 2011 Sep; 7(2):88-93. PubMed ID: 21794790
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF.
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [Abstract] [Full Text] [Related]

  • 8. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
    Narváez J, Díaz-Torné C, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.
    Semin Arthritis Rheum; 2011 Dec; 41(3):401-5. PubMed ID: 21862107
    [Abstract] [Full Text] [Related]

  • 9. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
    Rau R, Schleusser B, Herborn G, Karger T.
    J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
    [Abstract] [Full Text] [Related]

  • 10. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial.
    Karlsson JA, Neovius M, Nilsson JÅ, Petersson IF, Bratt J, van Vollenhoven RF, Ernestam S, Geborek P.
    Ann Rheum Dis; 2013 Dec; 72(12):1927-33. PubMed ID: 23196701
    [Abstract] [Full Text] [Related]

  • 11. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications.
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, Klein H, Moore GF.
    N Engl J Med; 1996 May 16; 334(20):1287-91. PubMed ID: 8609945
    [Abstract] [Full Text] [Related]

  • 12. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, Porter DR.
    Arthritis Rheum; 2008 May 16; 58(5):1310-7. PubMed ID: 18438851
    [Abstract] [Full Text] [Related]

  • 13. Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial.
    Eriksson JK, Neovius M, Bratt J, Petersson IF, van Vollenhoven RF, Geborek P, Ernestam S.
    JAMA Intern Med; 2013 Aug 12; 173(15):1407-14. PubMed ID: 23817631
    [Abstract] [Full Text] [Related]

  • 14. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.
    Arthritis Rheum; 2011 Oct 12; 63(10):2865-72. PubMed ID: 21647867
    [Abstract] [Full Text] [Related]

  • 15. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan 12; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 16. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr 12; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 17. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
    Matteson EL, Weyand CM, Fulbright JW, Christianson TJ, McClelland RL, Goronzy JJ.
    Rheumatology (Oxford); 2004 May 12; 43(5):619-25. PubMed ID: 14983105
    [Abstract] [Full Text] [Related]

  • 18. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
    Galindo-Rodriguez G, Aviña-Zubieta JA, Russell AS, Suarez-Almazor ME.
    J Rheumatol; 1999 Nov 12; 26(11):2337-43. PubMed ID: 10555887
    [Abstract] [Full Text] [Related]

  • 19. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V, Scott DL, Emery P, Kalden JR, Smolen JS, Cannon GW, Tugwell P, Crawford B, Leflunomide Rheumatoid Arthritis Investigators Groups.
    J Rheumatol; 2005 Apr 12; 32(4):590-601. PubMed ID: 15801012
    [Abstract] [Full Text] [Related]

  • 20. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.
    Ann Rheum Dis; 2007 Aug 12; 66(8):1059-65. PubMed ID: 17307765
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.